345 related articles for article (PubMed ID: 11129476)
1. Sequential designs for phase I clinical trials with late-onset toxicities.
Cheung YK; Chappell R
Biometrics; 2000 Dec; 56(4):1177-82. PubMed ID: 11129476
[TBL] [Abstract][Full Text] [Related]
2. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
Polley MY
Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
[TBL] [Abstract][Full Text] [Related]
3. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
4. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
5. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
[TBL] [Abstract][Full Text] [Related]
6. Using the time-to-event continual reassessment method in the presence of partial orders.
Wages NA; Conaway MR; O'Quigley J
Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
[TBL] [Abstract][Full Text] [Related]
7. Another look at two phase I clinical trial designs.
O'Quigley J
Stat Med; 1999 Oct; 18(20):2683-90; discussion 2691-2. PubMed ID: 10521858
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of dose-finding studies to observation errors.
Zohar S; O'Quigley J
Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
[TBL] [Abstract][Full Text] [Related]
9. How to design a dose-finding study using the continual reassessment method.
Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
[TBL] [Abstract][Full Text] [Related]
10. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
11. Monitoring late-onset toxicities in phase I trials using predicted risks.
Bekele BN; Ji Y; Shen Y; Thall PF
Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
[TBL] [Abstract][Full Text] [Related]
12. The continual reassessment method for dose-finding studies: a tutorial.
Garrett-Mayer E
Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalation designs in oncology: ADEPT and the CRM.
Shu J; O'Quigley J
Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
[TBL] [Abstract][Full Text] [Related]
14. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
Yuan Y; Lin R; Li D; Nie L; Warren KE
Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
[TBL] [Abstract][Full Text] [Related]
15. Continual reassessment method for partial ordering.
Wages NA; Conaway MR; O'Quigley J
Biometrics; 2011 Dec; 67(4):1555-63. PubMed ID: 21361888
[TBL] [Abstract][Full Text] [Related]
16. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
17. Dose-finding designs for cumulative toxicities using multiple constraints.
Lee SM; Ursino M; Cheung YK; Zohar S
Biostatistics; 2019 Jan; 20(1):17-29. PubMed ID: 29140414
[TBL] [Abstract][Full Text] [Related]
18. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.
Zhao L; Lee J; Mody R; Braun TM
Clin Trials; 2011 Aug; 8(4):361-9. PubMed ID: 21610004
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of phase I cancer clinical trial designs.
Ahn C
Stat Med; 1998 Jul; 17(14):1537-49. PubMed ID: 9699228
[TBL] [Abstract][Full Text] [Related]
20. Retrospective robustness of the continual reassessment method.
O'Quigley J; Zohar S
J Biopharm Stat; 2010 Sep; 20(5):1013-25. PubMed ID: 20721788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]